Etranacogene dezaparvovec (formerly AMT-061) is an investigational recombinant gene transfer therapy product designed to help patients with hemophilia B produce sufficient plasma levels of endogenous coagulation factor IX (FIX). The main therapeutic goal is long-term expression of FIX at levels steady enough to eliminate the need for routine prophylactic replacement therapy with exogenous FIX products.

If you have a Hayes login, click here to view the full report on the Knowledge Center.